Rochester, Minn.-based Mayo Clinic participated in the $123 million series C funding round for biotechnology company Senda Biosciences.
This latest funding round brings Senda Biosciences' total amount raised to $266 million. The funding will be used to finance clinical trials of Senda Biosciences' programmable medicines platform, according to the Aug. 17 Senda Biosciences news release.
Along with the Mayo Clinic, Flagship Pioneering, Samsung Life Sciences Fund and Stage 1 Ventures also participated in the funding round.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda CEO Guillaume Pfefer, PhD, said. "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."